Suppr超能文献

环形密封圈直线加速器屏蔽评估与管理方案的制定。

Development of shielding evaluation and management program for O-ring type linear accelerators.

机构信息

Department of Medicine, Yonsei University College of Medicine, Seoul, Korea.

Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, South Korea.

出版信息

Sci Rep. 2024 May 10;14(1):10719. doi: 10.1038/s41598-024-60362-6.

Abstract

The shielding parameters can vary depending on the geometrical structure of the linear accelerators (LINAC), treatment techniques, and beam energies. Recently, the introduction of O-ring type linear accelerators is increasing. The objective of this study is to evaluate the shielding parameters of new type of linac using a dedicated program developed by us named ORSE (O-ring type Radiation therapy equipment Shielding Evaluation). The shielding evaluation was conducted for a total of four treatment rooms including Elekta Unity, Varian Halcyon, and Accuray Tomotherapy. The developed program possesses the capability to calculate transmitted dose, maximum treatable patient capacity, and shielding wall thickness based on patient data. The doses were measured for five days using glass dosimeters to compare with the results of program. The IMRT factors and use factors obtained from patient data showed differences of up to 65.0% and 33.8%, respectively, compared to safety management report. The shielding evaluation conducted in each treatment room showed that the transmitted dose at every location was below 1% of the dose limit. The results of program and measurements showed a maximum difference of 0.003 mSv/week in transmitted dose. The ORSE program allows for the shielding evaluation results to the clinical environment of each institution based on patient data.

摘要

屏蔽参数可能因直线加速器 (LINAC) 的几何结构、治疗技术和射束能量而异。最近,O 型环直线加速器的引入正在增加。本研究的目的是使用我们开发的名为 ORSE(O 型环式放射治疗设备屏蔽评估)的专用程序来评估新型直线加速器的屏蔽参数。对总共四个治疗室进行了屏蔽评估,包括 Elekta Unity、Varian Halcyon 和 Accuray Tomotherapy。该开发的程序具有根据患者数据计算透射剂量、最大可治疗患者容量和屏蔽壁厚度的能力。使用玻璃剂量计测量了五天的剂量,以与程序的结果进行比较。从患者数据中获得的调强因子和使用因子与安全管理报告相比分别相差高达 65.0%和 33.8%。在每个治疗室进行的屏蔽评估表明,每个位置的透射剂量均低于剂量限值的 1%。程序和测量的结果显示,透射剂量的最大差异为 0.003 mSv/周。ORSE 程序允许根据患者数据对每个机构的临床环境进行屏蔽评估结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcf2/11087655/ea98971b6e54/41598_2024_60362_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验